Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (currently amended) An assay method for determining whether an agent is

capable of modulating the low affinity binding interaction of CCR5 with gp120, the method

comprising: incubating the agent with CCR5 and unlabelled gp120 to form a first reaction

mixture; adding an anti-gp120 antibody to said first reaction mixture to form a second reaction

mixture; and determining whether said agent modulates the interaction of CCR5 with gp120;

wherein said gp120 is associated with CD4, and wherein said low affinity binding has a

dissociation constant (Kd) of at least 200nM. and wherein said interaction is a low affinity

binding.

Claim 2. (cancelled)

Claim 3. (currently amended) The method according to claim 2 1, wherein said ligand

anti-gp120 antibody has a detectable label.

Claim 4. (previously presented) The method according to claim 3, wherein said

detectable label is a fluorescent atom or a fluorescent group.

Claim 5. (currently amended) The method according to claim 4, wherein said radioactive

fluorescent atom is Eu³⁺.

Claim 6. (cancelled)

Claim 7. (cancelled)

Claim 8. (cancelled)

Claim 9. (cancelled)

2

Appl. No. 09/759,841 Amendment dated January 10, 2004 Reply to Office Action of September 10, 2004

Claim 10. (cancelled)

Claim 11. (cancelled)

Claim 16. (newly presented) The method according to claim 1, wherein the method further comprises adding to said second reaction mixture a secondary antibody capable of binding to the anti-gp120 antibody.

Claim 17. (newly presented) The method according to claim 16, wherein said secondary antibody has a detectable label.

Claim 18. (newly presented) The method according to claim 17, wherein said detectable label is a fluorescent atom or a fluorescent group.

Claim 19. (newly presented) The method according to claim 18, wherein said fluorescent atom is Eu³⁺.

Claim 20. (newly presented) The method according to claim 16, wherein said secondary antibody is an anti-IgG antibody.

Claim 21. (newly presented) The method according to claim 1, wherein varying concentrations of said agent are incubated with a constant amount of gp120.